- Home
- PRKS vs NEO Comparison
PRKS vs NEO Comparison
Compare PRKS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRKS | NEO |
|---|---|---|
| Founded | 1959 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2012 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PRKS | NEO |
|---|---|---|
| Price | $45.22 | $16.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $47.50 | $13.38 |
| AVG Volume (30 Days) | 667.4K | ★ 2.3M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $1,263,324,000.00 | N/A |
| Revenue This Year | $3.45 | $10.63 |
| Revenue Next Year | $3.08 | $9.73 |
| P/E Ratio | $75.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.77 | $5.94 |
| 52 Week High | $56.95 | $16.92 |
Technical Indicators
Market Signals| Indicator | PRKS | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 60.35 |
| Support Level | $44.00 | $11.49 |
| Resistance Level | $49.08 | $16.92 |
| Average True Range (ATR) | 1.94 | 0.58 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 35.71 | 63.94 |
Price Performance
Historical ComparisonAbout PRKS United Parks & Resorts Inc.
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.